128 related articles for article (PubMed ID: 12613590)
1. Binding of an inhibitor of the p53/MDM2 interaction to MDM2.
Duncan SJ; Cooper MA; Williams DH
Chem Commun (Camb); 2003 Feb; (3):316-7. PubMed ID: 12613590
[TBL] [Abstract][Full Text] [Related]
2. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.
Duncan SJ; Grüschow S; Williams DH; McNicholas C; Purewal R; Hajek M; Gerlitz M; Martin S; Wrigley SK; Moore M
J Am Chem Soc; 2001 Jan; 123(4):554-60. PubMed ID: 11456567
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.
Cominetti MMD; Goffin SA; Raffel E; Turner KD; Ramoutar JC; O'Connell MA; Howell LA; Searcey M
Bioorg Med Chem Lett; 2015 Nov; 25(21):4878-4880. PubMed ID: 26115576
[TBL] [Abstract][Full Text] [Related]
4. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
[TBL] [Abstract][Full Text] [Related]
5. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
[TBL] [Abstract][Full Text] [Related]
7. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.
Galatin PS; Abraham DJ
J Med Chem; 2004 Aug; 47(17):4163-5. PubMed ID: 15293988
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
10. Solid-phase synthesis of the cyclic peptide portion of chlorofusin, an inhibitor of p53-MDM2 interactions.
Malkinson JP; Zloh M; Kadom M; Errington R; Smith PJ; Searcey M
Org Lett; 2003 Dec; 5(26):5051-4. PubMed ID: 14682762
[TBL] [Abstract][Full Text] [Related]
11. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
12. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
[TBL] [Abstract][Full Text] [Related]
13. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
[TBL] [Abstract][Full Text] [Related]
14. Turning the key on p53.
Lane DP; Fischer PM
Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
[No Abstract] [Full Text] [Related]
15. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.
Zheleva DI; Lane DP; Fischer PM
Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949
[TBL] [Abstract][Full Text] [Related]
16. Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction.
Fasan R; Dias RL; Moehle K; Zerbe O; Vrijbloed JW; Obrecht D; Robinson JA
Angew Chem Int Ed Engl; 2004 Apr; 43(16):2109-12. PubMed ID: 15083458
[No Abstract] [Full Text] [Related]
17. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
18. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization.
Kurki S; Latonen L; Laiho M
J Cell Sci; 2003 Oct; 116(Pt 19):3917-25. PubMed ID: 12915590
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?
Fischer PM; Lane DP
Trends Pharmacol Sci; 2004 Jul; 25(7):343-6. PubMed ID: 15219971
[No Abstract] [Full Text] [Related]
20. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.
Clark RC; Lee SY; Searcey M; Boger DL
Nat Prod Rep; 2009 Apr; 26(4):465-77. PubMed ID: 19642417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
